Drug Profile
Brostallicin - CTI BioPharma
Alternative Names: PNU-166196; PNU-166196A; SMi-BX1Latest Information Update: 28 Jun 2023
Price :
$50
*
At a glance
- Originator Pharmacia Corporation
- Developer CTI BioPharma; National Cancer Institute (USA); Systems Medicine
- Class Antineoplastics; DNA-binding proteins; Guanidines; Pyrroles; Small molecules
- Mechanism of Action Apoptosis stimulants; DNA inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Colorectal cancer; Soft tissue sarcoma; Triple negative breast cancer
Most Recent Events
- 26 Jun 2023 TI BioPharma has been acquired by Swedish Orphan Biovitrum
- 30 May 2014 Cell Therapeutics is now called CTI BioPharma
- 01 Jun 2013 Final efficacy data from a Phase-II trial in Breast cancer (Metastatic disease, Combination therapy) presented at the 49th Annual Meeting of the American Society of Clinical Oncology (ASCO-2013)